Udit Basak

Udit Basak

Auto-generated profile, based on publicly available information

Udit Basak

Department of Biological Sciences, Unified Academic Campus, Bose Institute, Kolkata, India

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 September 2025 in Cancer Control
Verified
Journal Article
Open access
SCSourio Chakraborty
Sourio Chakraborty
UBUdit Basak
Udit Basak
SMSumon Mukherjee
Sumon Mukherjee
SMSumoyee Mukherjee
Sumoyee Mukherjee
TDTanya Das
Tanya Das
Success of cancer immunotherapy (CIT) is intricately influenced by the tumor microenvironment (TME), a complex ecosystem that encompasses immune cells, stromal elements, and extracellular components. Despite the clinical breakthroughs of immune-checkpoint inhibitors (ICIs), adoptive cell therapies, cancer vaccines, and other immunotherapeutic interventions, many patients fail to respond and eventually die. Emerging evidence points to cancer stem cells (CSCs) as critical drivers of immune evasion, therapy-resistance, and tumor relapse. CSCs modulate the TME by secreting immune-suppressive factors, recruiting regulatory immune cells, and inducing phenotype-switching of anti-tumor TME subsets, thereby creating a protective niche that hinders immune surveillance. Conversely, the TME protects CSCs through hypoxia, altered metabolism, and immuno-suppressive cell populations. This bi-directional crosstalk supports tumor progression and provides resistance to immunotherapeutic strategies mainly by: (i) escaping immune-recognition and inhibiting active T cells via high immune-checkpoint molecule expression, (ii) creating immunosuppressive pro-tumor environment, and (iii) evading immune-mediated apoptosis of CSCs along with therapy-induced enrichment of their pool. Targeting CSCs in concert with reprogramming the TME via CSC-directed agents, metabolic modulators, or combinatorial immunotherapies, therefore, offers a promising avenue to overcome immunotherapy-resistance and achieve durable clinical responses. This review discusses the deeper mechanistic understanding of CSC-TME interactions, in light of designing next-generation immunotherapies with broader efficacy across diverse tumor types.

31 August 2023 in Exploration of Immunology
Verified
Journal Article
Open access
PDF file
SCSourio Chakraborty
Sourio Chakraborty
SMSumon Mukherjee
Sumon Mukherjee
UBUdit Basak
Udit Basak
SPSubhadip Pati
Subhadip Pati
ADApratim Dutta
Apratim Dutta
TDTanya Das
Tanya Das
Cancer stem cells (CSCs) are a small subpopulation of cells that drive the formation and progression of tumors. However, during tumor initiation, how CSCs communicate with neighbouring immune cells to overcome the powerful immune surveillance barrier in order to form, spread, and maintain the tumor, remains poorly understood. It is, therefore, absolutely necessary to understand how a small number of tumor-initiating cells (TICs) survive immune attack during (a) the “elimination phase” of “tumor immune-editing”, (b) the establishment of regional or distant tumor after metastasis, and (c) recurrence after therapy. Mounting evidence suggests that CSCs suppress the immune system through a variety of distinct mechanisms that ensure the survival of not only CSCs but also non-stem cancer cells (NSCCs), which eventually form the tumor mass. In this review article, the mechanisms via which CSCs change the immune landscape of the tissue of origin, which contains macrophages, dendritic cells (DCs), myeloid-derived suppressor cells (MDSCs), natural killer (NK) cells, and tumor-infiltrating lymphocytes, in favour of tumorigenesis were discussed. The failure of cancer immunotherapy might also be explained by such interaction between CSCs and immune cells. This review will shed light on the critical role of CSCs in tumor immune evasion and emphasize the importance of CSC-targeted immunotherapy as a cutting-edge technique for battling cancer by restricting communication between immune cells and CSCs.

1 November 2025 in Cancer Control
Verified
Journal Article
Open access
SMSumon Mukherjee
Sumon Mukherjee
SPSubhadip Pati
Subhadip Pati
SDSubhanki Dhar
Subhanki Dhar
TSTania Sarkar
Tania Sarkar
SPSilpita Paul
Silpita Paul
GSGaurisankar Sa
Gaurisankar Sa
Inflammation plays a pivotal role in every stage of cancer development, from tumor initiation to progression, largely by influencing the balance between immune surveillance and immune evasion. At the heart of this inflammatory signaling is the transcription factor Nuclear Factor κB (NFκB), widely recognized as a key orchestrator of immune responses in malignancies. Within the framework of cancer immunoediting, comprising the three key phases Elimination, Equilibrium, and Escape, NFκB emerges as a double-edged sword. While it can enhance the activity and infiltration of effector immune cells that promote tumor destruction, it can also reprogram these cells into immunosuppressive subsets, thereby facilitating tumor immune evasion and growth. This dual functionality makes NFκB both a promising and challenging target in cancer immunotherapy. Despite its significance, comprehensive insights into NFκB’s roles across the immunoediting continuum remain limited. This review aims to bridge that gap by systematically exploring the multifaceted contributions of NFκB in modulating tumor-immune interactions, from immune-mediated tumor surveillance to immune escape, highlighting its potential and complexity as a therapeutic target.

23 September 2025 in In Silico Research in Biomedicine
Verified
Journal Article
Open access
SCSourio Chakraborty
Sourio Chakraborty
UBUdit Basak
Udit Basak
ADApratim Dutta
Apratim Dutta
SMSumoyee Mukherjee
Sumoyee Mukherjee
GSGaurisankar Sa
Gaurisankar Sa
TDTanya Das
Tanya Das

21 August 2026 in Apoptosis
Verified
Journal Article
Closed access
PDF file
SCSourio Chakraborty
Sourio Chakraborty
SMSumon Mukherjee
Sumon Mukherjee
SGSubhajit Ghosh
Subhajit Ghosh
UBUdit Basak
Udit Basak
SMSumoyee Mukherjee
Sumoyee Mukherjee
TDTanya Das
Tanya Das